Perspective Therapeutics files routine corporate presentation update; no material new disclosure

Perspective Therapeutics, Inc.

Presentation shows [212Pb]VMT-α-NET Phase 1/2a data in NET with confirmed partial response in patient 103-105.
Tolerability data: mild, transient creatinine increase; no unexpected safety signals.
Pipeline includes [212Pb]VMT01 for melanoma and [212Pb]PSV359 targeting FAP-α in trials.
Pre-targeting platform and supply chain manufacturing infrastructure also highlighted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.